The vision to change the world
Life–changing therapy by global leaders in ophthalmology
Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.
Patented childhood myopia control therapy
Eyerising International’s Myopia Management Repeated Low-Level Red–Light (RLRL) therapy was conceived and developed by ERI’s Chief Medical Officer, Professor Mingguang He, a global leader in myopia control and the development of artificial intelligence systems in ophthalmology. This innovation in childhood myopia control meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.
View our most important scientific papers
News and press releases
Red light therapy device to feature at Myopia Progression in Children Conference 2023
Eyerising International will have its red light therapy device on display at the 2023 Myopia Progression in Children Conference (MPIC), featuring alongside many other new therapeutic interventions at the all-day event taking place in Sydney[...]
Shifting The Myopia Management Paradigm With Repeated Low-Level Red Light Therapy — Prof He Mingguang
Light exposure from spending time outdoors has been proven to prevent and slow down myopia. There is now an evidence-based medical device delivering low-level red light therapy that can help children reduce and even reverse[...]
The world’s first evidence-based, home-use, red-light therapy to manage myopia launched at the Asia Pacific Academy of Ophthalmology Congress (APAO) 2023 in Kuala Lumpur
The world’s first evidence-based, home-use, red-light therapy to manage myopia launched at the Asia Pacific Academy of Ophthalmology Congress (APAO) 2023 in Kuala Lumpur The patented Eyerising Myopia Management Device system has been clinically proven[...]
Axial Shortening in Myopic Children after Repeated Low-Level Red-Light Therapy: Post Hoc Analysis of a Randomized Trial
Axial length (AL) elongation in myopia is considered irreversible. We aimed to systemically report unexpected AL shortening observed in a randomized clinical trial (RCT) after repeated low-level red-light (RLRL) therapy. See full article >
Professor Mingguang He
Founder, Chief Medical Officer
Prof. He has over 25 years of experience in ophthalmology. He is currently a Professor of Ophthalmic Epidemiology at the University of Melbourne and leads ophthalmic epidemiology research at the Centre for Eye Research Australia. His research has led to original articles and invited editorials in respected medical journals, including the Journal of the American Medical Association, Diabetes Care, & Ophthalmology.
Jason Sun
Founder, MD
With a clinical background and over 20+ years of executive experience in the Australian health sector, including 10 years of industry development experience, Mr. Sun brings expertise in Medtech commercialisation, international business, regulatory compliance, and government relations.
Michael Woods
Executive Director
Mr. Woods has been an investor, adviser, board member, and CEO for various life science start-ups and scale-up companies in the life sciences sector.
Manny Pascual
Head of Commercial
Over 20 years of experience in the medical device industry Previous Marketing Director for CooperVision Asia Pacific Previous success in medical device company business expansion and acceleration.
David Holland
Business Development Manager (Australasia)
Federico Roma
CTO Accomplished technology leader
Dr. Yuri Aung
Clinical Affairs and RAQA Manager
Dr. Lisa Zhuoting Zhu
Director of Clinical Development
For any investor questions, please send your queries to:
Email: info@eyerisinginternational.com
Eyerising International Pty Ltd
Head office
Suite 2.05
9/11 Claremont St
South Yarra VIC 3141
